Mutation detail:
| Mutation site | 25521C>T |
| Virus | SARS-CoV-2 |
Mutation level  |
Nucleotide level |
| Gene/protein/region type | ORF8 |
| Gene ID | 43740577 |
| Country | Uruguay |
| Mutation type |
- |
| Genotype/subtype/clade | - |
| Sample |
Human |
| Variants | - |
| Viral reference sequence | NC_045512.2 |
| Drug/antibody/vaccine | - |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | ORF8 protein |
| Uniprot protein ID | P0DTC8 |
| Protein length | 121 amino acids |
| Protein description | The SARS-CoV-2 ORF8 gene spans 366 nucleotides (nt), is located between position 27,894 and 28,259 of the virus genome, following the ORF7b and preceding the N genes, respectively. The ORF8 gene is part of a hypervariable genomic region of - 430 bp in length that has been recognized as a recombination hotspot, also highly susceptible to deletions and nt substitutions. ORF8 protein comprehends an N-terminal signal peptide for transmembrane (TM) import and secretion, an internal -sandwich core and a C-terminal TM region followed by a stretch of basic residues. |
Literature information:
| Pubmed ID | 33306459 |
| Clinical information | No |
| Disease | - |
| Published year | 2021 |
| Journal | SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay |
| Title | SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay |
| Author | Victoria Elizondo,Gordon W Harkins,Batsirai Mabvakure,Sabine Smidt,Paul. |
| Evidence | Figure.5B |